Fig. 2.

MET treatment induces a time-related increase in the amount of FC RELN and GAD₆₇ promoters immunoprecipitated with MeCP2 or MBD2 antibodies. RELN (-520 to -225 bp) and GAD₆₇ (-760 to -329 bp) promoter fragments were quantified by using competitive PCR with internal standards (see Materials and Methods). (A1 and A2) The ratios are depicted between the amount of RELN (A1) and GAD₆₇ (A2) promoters immunoprecipitated with MeCP2 antibody (MeCP2-ChIP) and the amount of RELN and GAD₆₇ promoter fragments in the initial nonimmunoprecipitated extract (Input). (B1 and B2) The ratios are depicted between the amount of RELN (B1) and GAD₆₇ (B2) promoters immunoprecipitated with MBD2 antibody (MBD2-ChIP) and the amount of RELN and GAD₆₇ promoter fragments in the initial nonimmunoprecipitated extract (Input). VEH, vehicle; MET, methionine (5.2 mmol/kg s.c. twice a day; the last injection of MET was administered 2 h before killing). The data represent mean ± SE of three mice. ^*, P < 0.05 vs. vehicle treated group. ANOVA is followed by Dunnett's test.